Shingrix Uptake May Be Slowed By Part D Cost Sharing With Chart: Current Market Access to Shingrix

Since GlaxoSmithKline plc’s Shingrix (zoster vaccine recombinant, adjuvanted) launched in early 2018, a steady number of adults ages 50 and older have been getting the shingles vaccine. But a confusing patchwork o...
0 Comments
© 2025 MMIT

News Briefs

✦ The U.S. Court of Appeals for the Eighth Circuit on Aug. 7 sided with a PBM trade group in a legal challenge to a 2017 North Dakota law that regulates such firms. In Pharmaceutical Care Management Association v....
0 Comments
© 2025 MMIT

Pandemic Complicates, Doesn’t Stop Push to Lower Drug Costs

With a presidential election looming and the COVID-19 pandemic still raging, it might stand to reason that drug pricing reform efforts would be on the backburner. However, there are indications that policymakers rem...
0 Comments
© 2025 MMIT

Payers, Manufacturers Await Federal Vaccine Rollout Plan With Chart: How Close Are We to a Coronavirus Vaccine?

As the many COVID-19 vaccines under development barrel toward clinical trials for safety and efficacy (see infographic,below), questions remain about how they will be distributed when they become available. Payers a...
0 Comments
© 2025 MMIT

Care Deferral Dings OptumRx 2Q Earnings, Big RFP Wins

Although the steep decline in health care utilization tied to COVID-19 lockdowns proved to be an overall boon for UnitedHealth Group during the second quarter of 2020, that was not the case for the company’s PBM s...
0 Comments
© 2025 MMIT

Prime Signed Value-Based Deal With EMD Serono for Mavenclad

Prime Therapeutics LLC recently unveiled that it had signed a value-based agreement for a relatively new multiple sclerosis (MS) drug with a complicated treatment regimen and high price tag. In early June, the PB...
0 Comments
© 2025 MMIT

News Briefs

✦ Blue Cross and Blue Shield of North Carolina is offering certain customers up to a 33% discount on their copays for 90-day orders of maintenance medications. The policy, which became effective July 15, applies t...
0 Comments
© 2025 MMIT

DOJ, Drugmakers Renew Disputes Over Charitable Foundations

Two lawsuits — one against federal health regulators by a drugmaker and the other against a drugmaker by the Dept. of Justice — represent the latest salvos in the dispute over whether and how drug company-suppor...
0 Comments
© 2025 MMIT

IngenioRx Buys ZipDrug in Bid to Boost Adherence, Convenience

In what one expert calls a “logical” move for a PBM vying for business from cost-conscious payers, Anthem, Inc.’s IngenioRx said on July 6 that it acquired ZipDrug, a company that focuses on improving patients...
0 Comments
© 2025 MMIT

Scant Details, Comment Period for VBP Proposal Draw Concern

A new proposed rule (85 Fed. Reg. 37286, June 19, 2020), which CMS touted as a way to tweak Medicaid’s best-price provision to encourage more value-based purchasing (VBP) for expensive drugs, has drawn considerabl...
0 Comments
© 2025 MMIT